Ceramides in Long COVID

Ceramides, also described as Sphingolipids, belongs to the lipidomic group of Long COVID (PASC, Post-Acute Sequelae of COVID-19) markers and is reported to be decreased relative to recovered individuals without persistent symptoms (fully recovered). Clinically, it has been associated with mitochondrial dysfunction, membrane integrity. The evidence summarised here comes from Pérez-Mazliah et al. 2024 and reflects averages across cohorts rather than any single patient's result.

↓ ReducedLipidomic

Summary

Direction in Long COVID↓ Reduced — lower than in the comparison group
CategoryLipidomic
Also described asSphingolipids
Compared againstR (fully recovered) (recovered individuals without persistent symptoms (fully recovered))
Associated symptomsMitochondrial dysfunction, membrane integrity
Test typeBlood test (serum / plasma / whole blood)
SourcePérez-Mazliah et al. 2024 — doi:10.1021/acs.jproteome.3c00706
Condition atlasLong COVID Biomarker Atlas

Other conditions where Ceramides (plasma) is reported

See the cross-condition hub: Ceramides (plasma) across conditions.

Related Lipidomic markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is Ceramides high or low in Long COVID?

Reduced. Studies summarised in the OSMF atlas report lower Ceramides in Long COVID than in recovered individuals without persistent symptoms (fully recovered). Source: Pérez-Mazliah et al. 2024.

What symptoms is Ceramides associated with in Long COVID?

The cited literature associates this marker with Mitochondrial dysfunction, membrane integrity. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Ceramides?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Ceramides result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. Ceramides findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is Ceramides specific to Long COVID?

No. The same marker is also reported in ME/CFS in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). Ceramides in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/ceramides.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.